Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Atezolizumab + Tiragolumab for Lung Cancer
Recruiting2 awardsPhase 3
Fairfax, Virginia
This trial is testing a new immunotherapy combination to see if it's more effective than another immunotherapy drug in people with NSCLC who have had chemoradiotherapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service